GlassScriptPhysician profile
Karla Price
NPI 1457720526
$5,731.94
in general payments reported to CMS, 2019-2025
33 companies · $1,537 in 2025
The $1,537 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $285 · 2022: $966 · 2023: $1,390 · 2024: $1,553 · 2025: $1,537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,469 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,468.99 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,179.53 | 2021-2025 | |
| Lilly USA, LLC | $719.21 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $588.60 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $400.80 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $388.35 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $301.21 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $300.21 | 2021-2025 | Xifaxan |
| Exact Sciences Corporation | $264.14 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $196.08 | 2021-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.26 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $142.07 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $108.19 | 2021-2024 | |
| Dexcom, INC. | $95.36 | 2022-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $89.16 | 2022-2023 | Verquvo, Belsomra, Proquad |
| Azurity Pharmaceuticals, INC. | $87.91 | 2023-2025 | Edarbi, Edarbi |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $85.11 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $83.45 | 2024-2025 | Voquezna |
| Esperion Therapeutics, INC. | $80.92 | 2021-2025 | Nexletol |
| Insulet Corporation | $80.65 | 2023-2025 | Omnipod |
| Mylan Specialty L.P. | $60.67 | 2022-2023 | Yupelri |
| Axsome Therapeutics, INC. | $45.33 | 2022-2023 | Auvelity |
| Eisai INC. | $42.47 | 2024 | |
| Amarin Pharma, INC. | $37.82 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.56 | 2023-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $29.09 | 2022 | |
| Vanda Pharmaceuticals INC. | $22.40 | 2024 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $19.26 | 2024 | Rexulti |
| Viatris Specialty LLC | $19.13 | 2025 | Yupelri |
| Sunovion Pharmaceuticals INC. | $17.55 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.81 | 2025 | Spravato |
| Sanofi-Aventis U.S. LLC | $13.09 | 2022 | |
| Abbott Laboratories | $12.80 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.75 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.